Branded Generics Escape Indian Trade Margin Limits
This article was originally published in PharmAsia News
Executive Summary
Generic drugs with brand names in India could be excluded from the government's proposal to restrict trade margins. The exclusion would cover drug makers such as Cadita Healthcare, GlaxoSmithKline, Nicholas Piramal and Ranbaxy, all of which sell generics under brand names rather than chemical names. Those brand names place the drugs in another category under Indian law. Makers of the branded generics allow retail pharmacies a trade margin as high as 29 times the manufactured price. (Click here for more